Cassava Sciences (SAVA) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SAVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAVA, but not buy additional shares or sell existing shares.
View SAVA analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 1-year price targets for Cassava Sciences' shares. Their SAVA share price forecasts range from $11.00 to $124.00. On average, they expect the company's share price to reach $54.33 in the next year. This suggests a possible upside of 123.5% from the stock's current price.
View analysts price targets for SAVA or view top-rated stocks among Wall Street analysts.

Cassava Sciences' stock was trading at $29.54 at the start of the year. Since then, SAVA stock has decreased by 17.7% and is now trading at $24.31.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our SAVA earnings forecast.

Cassava Sciences, Inc. (NASDAQ:SAVA) posted its quarterly earnings results on Monday, May, 1st. The company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by $0.02.

ETFs with the largest weight of Cassava Sciences (NASDAQ:SAVA) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Invesco Dynamic Biotechnology & Genome ETF (PBE), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and iShares U.S. Pharmaceuticals ETF (IHE).Principal Healthcare Innovators ETF (BTEC).

Shares of Cassava Sciences reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Cassava Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.28%), State Street Corp (2.54%), Geode Capital Management LLC (1.82%), Gallacher Capital Management LLC (1.41%), Susquehanna International Group LLP (0.00%) and Charles Schwab Investment Management Inc. (0.70%). Insiders that own company stock include Eric Schoen, James William Kupiec, Remi Barbier, Richard Barry and Sanford Robertson.
View institutional ownership trends.

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SAVA stock can currently be purchased for approximately $24.31.

Cassava Sciences (NASDAQ:SAVA) has a market capitalization of $1.01 billion. The company earns $-76,250,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis.

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The official website for the company is www.cassavasciences.com. The company can be reached via phone at (512) 501-2444, via email at ir@paintrials.com, or via fax at 512-501-0414.